POLYMORPHISMS OF HPC2/ELAC2 AND SRD5A2
(5α-Reductase Type II) GENES IN PROSTATE CANCER
İzmirli M1,*, Arikan B2, Bayazit Y3, Alptekin D4
*Corresponding Author: Muzeyyen İzmirli, Department of Medical Biology, Faculty of Medicine, Bezmialem
Vakif University, 34093, Istanbul, Turkey; Tel.: +90-212-523-37-19, Fax: +90-212-523-23-26;
E-mail: muzeyyenizmirli@gmail.com.
page: 31
|
|
INTRODUCTION
Prostate cancer results from alteration of the balance
between cell proliferation and cell death in the
prostate gland. This cancer accounts for 32% of total
cancers in men [1]. Prostate cancer is caused by hormonal,
dietary, environmental and genetic factors. The
genes HPC2/ ELAC2, SRD5A2 (5α-reductase type II),
HPC1 (hereditary prostate cancer 1), AR (androgen receptor),
PSA (prostate specific antigen) are among the
genes responsible for it [1].
The HPC2/ELAC2 gene belongs to a family of prostate
cancer susceptibility genes which encode an evolutionarily
conserved metal-dependent hydrolase [1] that is
3’ processing endoribonuclease and to interact a component
of the mitotic apparatus is a γ tubulin. Thus, it is suggested
that the ELAC2 gene is associated with cell cycle
control [2,3]. The HPC1/ELAC2 protein contains 826
amino acids. Its gene is located on chromosome 17p11.2
and contains 24 exons. The are includes two recurrent
missense mutations (Ser217Leu and Ala541Thr) [4].
Steroid 5α-reductase type II irreversibly converts
testosterone to dihydrotestosterone in prostatic cells
[5,6]. Steroid 5α-reductase type II consists of 254
amino acids [7]. Its gene SRD5A2 contains five exons
[8] and 56.4 kb and is located on chromosome 2p22-
23. The single nucleotide polymorphisms in this gene
that have been studied in relation to prostate cancer are
Ala49Thr and Val89Leu [9]. We have investigated the relationship between Ser217Leu and Ala541Thr polymorphisms
in the HPC2/ELAC2 gene and Ala49Thr
and Val89Leu polymorphisms in the SRD5A2 gene in
Turkish men with prostate cancer.
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
